ADC Therapeutics (ADCT) Operating Income (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly Operating Income of -$25.2 million for Q1 2026, up 11.31% year-on-year from -$22.7 million in Q1 2025, and up 18.48% on a QoQ basis from -$31.0 million in Q3 2025.
ADC Therapeutics (ADCT) Operating Income (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Operating Income for 7 consecutive years, with -$25.2 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | -25.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.25 Mn |
| Sep 30, 2025 | -30.97 Mn |
| Jun 30, 2025 | -44.15 Mn |
| Mar 31, 2025 | -28.46 Mn |
| Sep 30, 2024 | -35.56 Mn |
| Jun 30, 2024 | -29.04 Mn |
| Mar 31, 2024 | -33.61 Mn |
| Sep 30, 2023 | -36.15 Mn |
| Jun 30, 2023 | -39.65 Mn |
| Mar 31, 2023 | -51.57 Mn |
| Sep 30, 2022 | -3.11 Mn |
| Jun 30, 2022 | -69.41 Mn |
| Mar 31, 2022 | -40.36 Mn |
| Sep 30, 2021 | -57.79 Mn |
| Jun 30, 2021 | -70.48 Mn |
| Mar 31, 2021 | -70.67 Mn |
| Sep 30, 2020 | -52.43 Mn |
| Jun 30, 2020 | -44.95 Mn |
| Mar 31, 2020 | -43.89 Mn |